Decera Clinical Education Oncology Podcast

In this episode, Jyoti D. Patel, MD, and Diwakar Davar, MD, discuss several studies investigating agents targeting TIGIT, an emerging immune checkpoint target with promising early-phase clinical trial results. The episode includes a comprehensive explanation of TIGIT, how the TIGIT pathway functions, and the potential role of TIGIT inhibition for the treatment of cancer, including analyses from ongoing clinical trials such as CITYSCAPE, PACIFIC-8, ARC-7, and SKYSCRAPER-01.Presenters:Jyoti D. Patel, MDProfessor of MedicineDivision of Hematology and OncologyMedical Director for Thoracic OncologyAssistant Director for Clinical ResearchAssociate Vice Chair of Clinical ResearchDepartment of MedicineRobert H. Lurie Comprehensive Cancer CenterNorthwestern UniversityChicago, IllinoisDiwakar Davar, MDAssistant Professor, Melanoma and Phase I TherapeuticsDivision of Hematology/OncologyDepartment of MedicineUniversity of Pittsburgh Hillman Cancer CenterPittsburgh, PennsylvaniaLink to the complete program, including an online text module with downloadable slidesets, ClinicalThought commentaries, and an additional podcast on this topic:https://bit.ly/3r9BLmB Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Nilofer S. Azad, MD, and Kanwal Raghav, MD, discuss current and emerging uses of regorafenib and TAS-102 in later-line treatment of patients with mCRC, with topics including:Current use of regorafenib and TAS-102 monotherapyCombination therapy with regorafenib and PD-1 inhibitorsAdding bevacizumab to TAS-102Presenters:Nilofer S. Azad, MD  Professor, Oncology  Sidney Kimmel Comprehensive Cancer Center  Johns Hopkins UniversityBaltimore, Maryland  Kanwal Raghav, MDAssociate Professor, GI Medical Oncology  University of Texas MD Anderson Cancer CenterHouston, Texas  Content based on an online CME program supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.Follow along with the slideset:https://bit.ly/3NLejWeLink to full program:https://bit.ly/33yrIyh Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jeff P. Sharman, MD; Matthew S. Davids, MD, MMSc; and Anthony Mato, MD, MSCE, answer questions from a live CCO webinar on current best practices and  emerging strategies in BTK inhibitor therapy for patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), with questions including:For patients with CLL, when should acalabrutinib-, ibrutinib-, or venetoclax-based regimens be considered?What is the optimal therapy for a patient with del(17p) CLL?When should an anti-CD20 antibody be added to BTK inhibitor therapy for patients with CLL?What are best practices in the use of BTK inhibitors for patients with MCL?How can BTK inhibitor resistance occur?How might investigational noncovalent BTK inhibitors be used should they be approved?What are key adverse events with BTK inhibitors?Presenters:Jeff P. Sharman, MD (chair)Medical DirectorHematology ResearchUS Oncology Willamette Valley Cancer InstituteEugene, Oregon Matthew S. Davids, MD, MMScAssociate Professor of MedicineHarvard Medical SchoolDirector of Clinical ResearchDivision of LymphomaDana-Farber Cancer InstituteBoston, MassachusettsAnthony Mato, MD, MSCEAssociate ProfessorDivision of LeukemiaMemorial Sloan Kettering Cancer CenterNew York, New YorkContent based on an online CME program supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit https://bit.ly/3wXOsV5. Link to full program:https://bit.ly/3NEpsYQ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Lipika Goyal, MD, leads an engaging discussion with Christine Chio, PharmD, BCOP, and Caroline Kuhlman, NP, on current treatment of patients with cholangiocarcinoma. Topics include:Initial diagnosisBiomarker testing to guide treatment with immunotherapies and targeted agentsAdverse event managementStrategies for counseling patientsPresenters:Christine Chio, PharmD, BCOPClinical Ambulatory GI Oncology PharmacistDepartment of PharmacyMassachusetts General HospitalBoston, MassachusettsLipika Goyal, MDAssistant Professor of MedicineDivision of Hematology/OncologyDepartment of MedicineHarvard Medical SchoolAttending PhysicianMassachusetts General Hospital Cancer CenterBoston, MassachusettsCaroline Kuhlman, NPDepartment of Gastrointestinal OncologyMassachusetts General Hospital Cancer CenterBoston, MassachusettsLink to the full program on the CCO website: https://bit.ly/3JGDBCk  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Amy DeZern, MD, MHS, Daniel Pollyea, MD, MS, and Amer Zeidan, MBBS, discuss challenging cases in MDS, includingTreatment for MDS after ESA failureStrategies for patients with intermediate- or high-risk MDSLuspatercept therapy in MDSMDS case challengesLink to full program, including downloadable slidesets:https://bit.ly/3tYwcYuPresenters: Amy E. DeZern, MD, MHSAssociate ProfessorOncology and MedicineThe Johns Hopkins University School of MedicineBaltimore, MarylandDaniel Pollyea, MD, MSAssociate Professor of MedicineClinical Director of Leukemia ServicesDivision of HematologyUniversity of Colorado School of MedicineAurora, ColoradoAmer Zeidan, MBBSAssociate Professor, Internal MedicineHematologyYale UniversityNew Haven, Connecticut Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Dr Prithviraj Bose, Pharmacist Caitlin R. Rausch, and Nurse Practitioner Ilene A. Galinsky discuss incorporating KIT-targeted therapies into management of patients with advanced systemic mastocytosis. Topics include:Diagnosis and prognosis of advanced systemic mastocytosisClinical trial data on efficacy of avapritinib and midostaurinMonitoring for and managing key toxicities with avapritinib, including cognitive dysfunctionPresenters:Prithviraj Bose, MDAssociate ProfessorDivision of Cancer MedicineDepartment of LeukemiaThe University of Texas MD Anderson Cancer CenterHouston, TexasCaitlin R. Rausch, PharmDClinical Pharmacy Specialist, LeukemiaDivision of PharmacyUniversity of Texas MD Anderson Cancer CenterHouston, TexasIlene A. Galinsky, NPSenior Research Program Adult Leukemia Nurse PractitionerDepartment of LeukemiaDana-Farber Cancer Institute/Brigham and Women's HospitalBoston, Massachusetts Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Julie M. Vose, MD, MBA;  Brad S. Kahl, MD; and  John P. Leonard, MD, discuss treatment approaches for patients with B-cell lymphomas, including information on: Follicular lymphomaMarginal zone lymphomaMantle cell lymphomaDiffuse large B-cell lymphomaPosttransplant lymphoproliferative disorderPresenters:Julie M. Vose, MD, MBAChief, Division of Oncology and HematologyNeumann M. and Mildred E. Harris ProfessorDepartment of Internal MedicineUniversity of Nebraska Medical CenterOmaha, NebraskaBrad S. Kahl, MDProfessor of MedicineDepartment of Medical OncologyWashington University School of MedicineSt Louis, MissouriJohn P. Leonard, MDRichard T. Silver Distinguished Professor of Hematology and Medical OncologyProfessor of MedicineWeill Cornell MedicineNew York Presbyterian HospitalNew York, New YorkLink to the complete program, including downloadable slidesets, expert commentaries, an on-demand webcast, and treatment resource guides:https://bit.ly/3tb47wU Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode from Clinical Care Options (CCO), Josep M. Llovet, MD, PhD, and Markus Peck-Radosavljevic, MD, MBA, discuss second line treatment of patients with advanced hepatocellular carcinoma. Topics include:Available agents for the management of advanced hepatocellular carcinoma in the second lineThe current role of tyrosine kinase inhibitors in second-line treatment of advanced hepatocellular carcinomaOngoing clinical trials in the second-line settingPresenters:  Josep M. Llovet, MD, PhD, FAASLDProfessor of MedicineDirector, Mount Sinai Liver Cancer ProgramDivision of Liver DiseasesMount Sinai School of MedicineNew York, New YorkProfessor of ResearchLiver Unit, IDIBAPSHospital Clinic BarcelonaBarcelona, SpainUniv. Prof. Markus Peck-Radosavljevic, MD, MBAProfessor of MedicineMedical University of ViennaVienna, AustriaDepartment Chair, Innere Medizin und GastroenterologieKlinikum Klagenfurt am WörtherseeKlagenfurt am Wörthersee, AustriaLink to full program, including accompanying downloadable slidesets:https://bit.ly/2ZL9bxq Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Eileen M. O’Reilly, MD, and Naureen Starling, MD, FRCP,  discuss emerging therapeutic strategies involving PARP inhibitor therapy in the treatment of pancreatic cancer. Topics include:Current treatment landscape and testing in the United States vs the United Kingdom  Testing for molecular subgroups beyond BRCAmUsing PARP inhibitors in earlier stages of the diseaseLearning from other cancers, such as prostate, breast, and ovarian  Presenters:Eileen M. O’Reilly, MDWinthrop Rockefeller Chair in Medical OncologySection Head, Hepatopancreaticobiliary/Neuroendocrine CancersGastrointestinal Oncology ServiceAssociate DirectorDavid M. Rubenstein Center for Pancreatic CancerAttending Physician, MemberMemorial Sloan Kettering Cancer CenterProfessor of MedicineWeill Medical CollegeNew York, New York, USANaureen Starling, MD, FRCPAssociate Director of Clinical ResearchDepartment of GI CancersConsultant Medical Oncologist, GI CancersThe Royal Marsden HospitalLondon, United KingdomContent based on an online CME program supported by an educational grant from AstraZeneca.Link to full program:https://bit.ly/3s6AnSz Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode,Brian G.M. Durie, MD; Thomas G. Martin, MD; Philippe Moreau, MD; S. Vincent Rajkumar, MD; and Jesús F. San-Miguel, MD, PhD, discuss treatment approaches for multiple myeloma using example patient cases.Smoldering myelomaInduction therapy for autologous stem cell transplant–eligible patientsFirst-line approaches for autologous stem cell transplant–ineligible patientsTreatment after first relapseSelecting therapy for heavily pretreated myelomaPresenters:Brian G.M. Durie, MDMedical Director, AMyCCo-Chair Myeloma Committee, SWOGChairman, International Myeloma FoundationSpecialist in Multiple Myeloma and Related DisordersCedars-Sinai Outpatient Cancer CenterLos Angeles, CaliforniaThomas G. Martin, MDClinical Professor of MedicineAssociate Director, Myeloma ProgramUniversity of California, San Francisco Medical CenterSan Francisco, CaliforniaPhilippe Moreau, MDProfessor of Clinical HematologyHead, Hematology DepartmentUniversity Hospital Hôtel-DieuNantes, FranceS. Vincent Rajkumar, MDEdward W. and Betty Knight Scripps Professor of MedicineMayo ClinicRochester, MinnesotaJesús F. San-Miguel, MD, PhDDirector of Clinical and Translational MedicineUniversidad de NavarraPamplona, SpainLink to the complete program, including downloadable slidesets, an expert commentary, an on-demand webcast, and treatment resource guide.https://bit.ly/3JJbWk9 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.